<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        23-110-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MERONEM 1GM VIAL I-V
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MEROPENEM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        g
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        powder for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        890.60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ACS DOBFAR SPA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ACS DOBFAR SPA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DH02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Meronemcontains the active substance meropenem and belongs to a group of medicines called carbapenem antibiotics. It works by killing bacteria, which can cause serious infections.</p><p>Meronem is used to treat the following in adults and children aged 3 months and older:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection affecting the lungs (pneumonia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lung and bronchial infections in patients suffering from cystic fibrosis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated urinary tract infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated infections in the abdomen</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections that you can catch during or after the delivery</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated skin and soft tissues infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute bacterial infection of the brain (meningitis)</p><p>Meronem may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.</p><p>Meropenem may be used to treat bacterial infection of the blood which might be associated with a type of infection mentioned above.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Meronem if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic (hypersensitive) to meropenem or any of the other ingredients of this medicine (listed in Section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic (hypersensitive) to other antibiotics such as penicillins, cephalosporins, or carbapenems as you may also be allergic to meropenem.</p><p>Warnings and precautions</p><p>Talk to your doctor, pharmacist or nurse before using Meronem if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have health problems, such as liver or kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had severe diarrhoea after taking other antibiotics.</p><p>You may develop a positive test (Coombs test) which indicates the presence of antibodies that may destroy red blood cells. Your doctor will discuss this with you.</p><p>You may develop signs and symptoms of severe skin reactions (see section 4). If this happens talk to your doctor or nurse immediately so that they can treat the symptoms.</p><p>If you are not sure if any of the above applies to you, talk to your doctor or nurse before using Meronem.</p><p><strong>Other medicines and Meronem</strong></p><p>Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. This is because Meronem can affect the way some medicines work and some medicines can have an effect on Meronem.</p><p>In particular, tell your doctor, pharmacist or nurse if you are taking any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Probenecid (used to treat gout).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Valproic acid/sodium valproate/valpromide (used to treat epilepsy). Meronem should not be used because it may decrease the effect of sodium valproate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oral anti-coagulant agent (used to treat<em> </em>or prevent blood clots).</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. It is preferable to avoid the use of meropenem during pregnancy. Your doctor will decide whether you should use Meronem.</p><p>It is important that you tell your doctor if you are breast-feeding or if you intend to breast-feed before receiving meropenem. Small amounts of this medicine may pass into the breast milk. Therefore, your doctor will decide whether you should use Meronem while breast-feeding.</p><p>Driving and using machines</p><p>No studies on the effect on the ability to drive and use machines have been performed.</p><p>Meronem has been associated with headache and tingling or pricking skin (paraesthesia). Any of these side effects could affect your ability to drive or operate machines.</p><p>Meronem may cause involuntary muscle movements which may cause the person&#39;s body to shake rapidly and uncontrollably (convulsions). This is usually accompanied with a loss of consciousness. Do not drive or use machines if you experience this side effect.</p><p><strong>&nbsp;</strong></p><p><strong>Meronem contains sodium</strong></p><p>Meronem 500&nbsp;mg: This medicine contains 45 mg sodium (main component of cooking/table salt) in each 500 mg dose. This is equivalent to 2.25% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p>Meronem 1&nbsp;g: This medicine contains 90 mg sodium (main component of cooking/table salt) in each 1&nbsp;g dose. This is equivalent to 4.5% of the recommended maximum daily dietary intake of sodium for an adult.</p><p><strong>Advice/medical education</strong></p><p>Antibiotics are used to treat infections caused by bacteria. They have no effect against infections caused by viruses.</p><p>Sometimes an infection caused by bacteria does not respond to a course of an antibiotic. One of the commonest reasons for this to occur is because the bacteria causing the infection are resistant to the antibiotic that is being taken. This means that they can survive and even multiply despite the antibiotic.</p><p>Bacteria can become resistant to antibiotics for many reasons. Using antibiotics carefully can help to reduce the chance of bacteria becoming resistant to them.</p><p>When your doctor prescribes a course of an antibiotic it is intended to treat only your current illness. Paying attention to the following advice will help prevent the emergence of resistant bacteria that could stop the antibiotic working.</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp; It is very important that you take the antibiotic at the right dose, at the right times and for the right number of days. Read the instructions on the label and if you do not understand anything ask your doctor or pharmacist to explain.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; You should not take an antibiotic unless it has been prescribed specifically for you and you should use it only to treat the infection for which it was prescribed.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp; You should not take antibiotics that have been prescribed for other people even if they had an infection that was similar to yours.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp; You should not give antibiotics that were prescribed for you to other people.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp; If you have any antibiotic left over when you have taken the course as directed by your doctor you should take the remainder to a pharmacy for appropriate disposal.</p><p>&nbsp;</p><p>If you have a condition which requires you to monitor your sodium intake please inform your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>Use in adults</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The dose depends on the type of infection that you have, where the infection is in the body and how serious the infection is. Your doctor will decide on the dose that you need.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The dose for adults is usually between 500&nbsp;mg (milligrams) and 2&nbsp;g (gram). You will usually receive a dose every 8 hours. However you may receive a dose less often if your kidneys do not work very well.</p><p>Use in children and adolescents</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The dose for children over 3 months old and up to 12 years of age is decided using the age and weight of the child. The usual dose is between 10&nbsp;mg and 40&nbsp;mg of Meronem for each kilogram (kg) that the child weighs. A dose is usually given every 8 hours. Children who weigh over 50&nbsp;kg will be given an adult dose.</p><p><strong>How to use Meronem</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Meronem will be given to you as an injection or infusion into a large vein.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor or nurse will normally give Meronem to you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; However, some patients, parents and carers are trained to give Meronem at home. Instructions for doing this are provided in this leaflet (in the section called &lsquo;Instructions for giving Meronem to yourself or someone else at home&rsquo;). Always use Meronem exactly as your doctor has told you. You should check with your doctor if you are not sure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your injection should not be mixed with or added to solutions that contain other medicines.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The injection may take about 5&nbsp;minutes or between 15 and 30&nbsp;minutes. Your doctor will tell you how to give Meronem.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You should normally have your injections at the same times each day.</p><p>If you use more Meronem than you should</p><p>If you accidentally use more than your prescribed dose, contact your doctor or nearest hospital straight away.</p><p>If you forget to use Meronem</p><p>If you miss an injection, you should have it as soon as possible. However, if it is almost time for your next injection, skip the missed injection. Do not have a double dose (two injections at the same time) to make up for a forgotten dose.</p><p>If you stop using Meronem</p><p>Do not stop having Meronem until your doctor tells you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Severe allergic reactions</p><p>If you have any of these signs and symptoms, <strong>tell your doctor or nurse straight away</strong>. You may need urgent medical treatment. The signs and symptoms may include a sudden onset of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe rash, itching or hives on the skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, lips, tongue or other parts of the body.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath, wheezing or trouble breathing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious skin reactions which include</p><p>o&nbsp;&nbsp; Serious hypersensitivity reactions involving fever, skin rash, and changes in the blood tests that check how the liver is working (increased levels of liver enzymes) and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes. These may be signs of a multi-organ sensitivity disorder known as DRESS syndrome.</p><p>o&nbsp;&nbsp; Severe red scaly rash, skin bumps that contain pus, blisters or peeling of skin, which may be associated with a high fever and joint pain.</p><p>o&nbsp;&nbsp; Severe skin rashes that can appear as reddish circular patches often with central blisters on the trunk, skin peeling, ulcers of mouth, throat, nose, genitals and eyes and can be preceded by fever and flu-like symptoms (Stevens-Johnson syndrome) or a more severe form (toxic epidermal necrolysis).</p><p>&nbsp;</p><p>Damage to red blood cells (not known)</p><p>The signs include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being breathless when you do not expect it.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Red or brown urine.</p><p>If you notice any of the above, <strong>see a doctor straight away</strong>.</p><p>Other possible side effects:</p><p>Common (may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abdominal (stomach) pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick (nausea).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being sick (vomiting).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash, itchy skin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain and inflammation.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased numbers of platelets in your blood (shown in a blood test).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in blood tests, including tests that show how well your liver is working.</p><p>Uncommon (may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in your blood. These include reduced numbers of platelets (which may make you bruise more easily), increased numbers of some white blood cells, decreased numbers of other white cells and increased amounts of a substance called &lsquo;bilirubin&rsquo;. Your doctor may do blood tests from time to time.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in blood tests, including tests that show how well your kidney is working.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A tingling feeling (pins and needles).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections of the mouth or the vagina that are caused by a fungus (thrush).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the bowel with diarrhoea.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sore veins where Meronem is injected.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other changes in your blood. The symptoms include frequent infections, high temperature and sore throat. Your doctor may do blood tests from time to time.</p><p>&nbsp;</p><p>Rare (may affect up to 1 in 1,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fits (convulsions).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute disorientation and confusion (delirium).</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Sudden chest pain</strong>, which may be a sign of a potentially serious allergic reaction called Kounis syndrome has been noted with other medicines of the same type. If this happens talk to a doctor or nurse immediately.</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly (see details below). By reporting side effects you can help provide more information on the safety of this medicine.</p><p><strong>To report any side effect(s):</strong></p><p>&bull;&nbsp;&nbsp;&nbsp; Saudi Arabia:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center ( NPC )</strong></p><ul><li>Call center: 19999</li></ul><p>&middot;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp; Website : https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC states:</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority </em></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use Meronem IV after the expiry date which is stated on the container. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30&deg;C.</p><p>&nbsp;</p><p><strong><u>Injection</u></strong></p><p>After reconstitution: The reconstituted solutions for intravenous injection should be used immediately. The time interval between the beginning of reconstitution and the end of intravenous injection should not exceed:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3&nbsp;hours when stored at up to 25&deg;C;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12&nbsp;hours when stored under refrigerated conditions (2-8&deg;C).</p><p><strong>Infusion</strong></p><p>After reconstitution: The reconstituted solutions for intravenous infusion should be used immediately. The time interval between the beginning of reconstitution and the end of intravenous infusion should not exceed:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3&nbsp;hours when stored at up to 25&deg;C when Meronem is dissolved in sodium chloride;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24&nbsp;hours when stored under refrigerated conditions (2-8&deg;C) when Meronem is dissolved in sodium chloride;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; when Meronem is dissolved in dextrose the solution should be used immediately.</p><p>&nbsp;</p><p>From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately.</p><p>If not used immediately in-use storage times and conditions are the responsibility of the user.</p><p>Do not freeze the reconstituted solution.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is meropenem trihydrate equivalent to 500 mg anhydrous meropenem.</p><p>The active substance is meropenem trihydrate equivalent to 1 g anhydrous meropenem.</p><p>The other ingredient is Anhydrous Sodium carbonate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                •	Meronem is a white to light yellow powder for solution for injection or infusion in a vial. 
Pack sizes of 10 vials.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing authorization holder:</p><p>Pfizer Limited,</p><p>Ramsgate Road,Kent , CT 13, 9 NJ, Sandwich, United kingdom</p><p>&nbsp;</p><p><strong>Manufacturer</strong>:</p><p>ACS Dobfar SpA, Tribiano, Milan,</p><p>Italy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May 2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي ميرونيم على المادة الفعالة ميروبينيم وينتمي إلى مجموعة من الأدوية تسمى مضادات كاربابينيم الحيوية. وهو يعمل عن طريق القضاء على البكتيريا التي يمكن أن تسبب حالات عدوى خطيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم ميرونيم لعلاج الحالات التالية لدى البالغين والأطفال في عمر ۳ أشهر فأكثر:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى التي تصيب الرئتين (الالتهاب الرئوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات عدوى الرئة والشعب الهوائية لدى المرضى الذين يعانون من التليف الكيسي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات عدوى المسالك البولية المعقدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى المعقدة في البطن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى التي يمكن أن تصابي بها أثناء الولادة أو بعدها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى المعقدة بالجلد والأنسجة الرخوة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى البكتيرية الحادة بالدماغ (التهاب السحايا)</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يُستخدم ميرونيم في إدارة حالة المرضى المصابين بقلة العدلات وحمى يُشتبه في أنها ناتجة عن عدوى بكتيرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يُستخدم ميروبينيم لعلاج العدوى البكتيرية في الدم التي قد تكون مرتبطة بأحد أنواع العدوى المذكورة أعلاه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="right" style="width:100%"><tbody><tr><td style="vertical-align:bottom"><p dir="RTL">أ&zwnj;-&nbsp; موانع استعمال ميرونيم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية (فرط حساسية) تجاه ميروبينيم وأي مكونات أخرى لهذا الدواء (المدرجة في القسم ٦).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت &nbsp;مصابًا &nbsp;بالحساسية &nbsp;(فرط الحساسية) تجاه مضادات حيوية أخرى مثل مركبات البنسلين، أو مركبات سيفالوسبورين، أو مركبات كاربابينيم حيث قد تكون مصابًا بالحساسية أيضًا تجاه ميروبينيم.</p><p dir="RTL">&nbsp;</p><p>ب&zwnj;-&nbsp; الاحتياطات عند استعمال ميرونيم</p><p dir="RTL">قم بالتواصل مع الطبيب أو الصيدلي أو الممرض(ة) قبل استخدام المستحضر:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات صحية، مثل مشكلات الكبد أو الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت بإسهال شديد بعد تناول مضادات حيوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تظهر نتيجة إيجابية لأحد الاختبارات (اختبار كومبس) التي تخضع لها مما يشير إلى وجود أجسام مضادة قد تدمر خلايا الدم الحمراء. سيناقش الطبيب هذا الأمر معك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تظهر عليك علامات وأعراض تفاعلات جلدية شديدة (انظر القسم ٤). إذا حدث هذا، فتحدث إلى طبيبك أو الممرضة على الفور حتى يستطيعا علاج الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا &nbsp;مما إذا كانت أي من الحالات الواردة أعلاه تنطبق عليك أم لا، فتحدث إلى طبيبك أو الممرض (ة) قبل استخدام ميرونيم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p>ج- التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية.</p><p dir="RTL">أخبر الطبيب أو الصيدلي أو الممرض (ة) في حال تناولت (أو كنت تتناول مؤخرًا) أي أدوية أخرى. وهذا نظرًا لأن ميرونيم يمكن أن يؤثر على طريقة عمل بعض الأدوية ويمكن أن تؤثر بعض الأدوية على ميرونيم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وبشكل خاص، أخبر طبيبك أو الصيدلي أو الممرض (ة) إذا كنت تتناول أيًا &nbsp;من الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروبينيسيد (يستخدم لعلاج النقرس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمض الفالبرويك/فالبروات الصوديوم/فالبروميد (يستخدم لعلاج الصرع). ينبغي عدم استخدام ميرونيم لأنه قد يقلل تأثير فالبروات الصوديوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العوامل المضادة للتجلط التي تؤخذ عن طريق الفم (تستخدم لعلاج الجلطات الدموية أو منعها).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>د- الحمل والرضاعة</p><p dir="RTL">إذا كنتِ حاملًا أو تُرضعين رضاعة طبيعية أو تعتقدين أنكِ ربما تكونين حاملًا &nbsp;أو &nbsp;تخططين للحمل فاستشيري الطبيب أو الصيدلي قبل استخدام هذا الدواء. يفضل تجنب استخدام ميروبينيم أثناء الحمل. سيقرر طبيبكِ &nbsp;ما &nbsp;إذا كان ينبغي أن تستخدمي ميرونيم أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم أن تخبري طبيبكِ إذا كنتِ تُرضعين رضاعة طبيعية أو إذا كنتِ &nbsp;تخططين &nbsp;للقيام بالرضاعة الطبيعية قبل تلقي ميروبينيم. قد تمر كميات صغيرة من هذا الدواء إلى لبن الثدي. لذلك سيقرر &nbsp;طبيبكِ &nbsp;إذا ما كان ينبغي أن تستخدمي ميرونيم أثناء الرضاعة الطبيعية أم لا.</p><p dir="RTL">&nbsp;</p><p>هـ- تأثير ميرونيم على القيادة واستخدام الآلات</p><p dir="RTL">لم تُجر دراسات حول التأثير على القدرة على القيادة واستخدام الآلات. لقد ارتبط استخدام ميرونيم بالصداع والشعور بالوخز أو الخدر في الجلد (المذل). قد يؤثر أي من هذه الآثار الجانبية على قدرتك على القيادة أو تشغيل الآلات. يمكن أن يسبب ميرونيم حركات لاإرادية في العضلات مما قد يؤدي إلى ارتعاش جسد الشخص بسرعة وبطريقة خارجة عن السيطرة (تشنجات). تكون هذه الأعراض مصحوبة عادة بفقدان الوعي. لا تقم بالقيادة أو تستخدم الآلات إذا أصبت بهذه الآثار الجانبية.</p><p dir="RTL">&nbsp;</p><p>و- معلومات هامة حول بعض مكونات ميرونيم</p><p>يحتوي ميرونيم على الصوديوم</p><p dir="RTL">&nbsp;</p><p dir="RTL">ميرونيم ٥۰۰ ملجم: يحتوي هذا الدواء على ٤٥ ملجم من الصوديوم (المكون الرئيسي لملح الطهي/الطعام) في كل جرعة قدرها ٥۰۰ ملجم. هذا يكافئ ۲,۲٥ ٪ من الحد الأقصى للمدخول الغذائي اليومي الموصى به من الصوديوم للبالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ميرونيم ۱ جم: يحتوي هذا الدواء على ٩۰ ملجم من الصوديوم (المكون الرئيسي لملح الطهي/الطعام) في كل جرعة قدرها ۱ جم. هذا يكافئ ٤,٥ ٪ من الحد الأقصى للمدخول الغذائي اليومي الموصى به من الصوديوم للبالغين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>النصائح/التثقيف الطبي</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">تُستخدم المضادات الحيوية لعلاج حالات العدوى التي تسببها البكتيريا. وليس لها أي تأثير على حالات العدوى التي تسببها الفيروسات.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">في بعض الأحيان، لا تستجيب عدوى ناتجة عن البكتيريا لدورة علاجية من أحد المضادات الحيوية. أحد الأسباب الأكثر شيوعًا لحدوث ذلك هو أن البكتيريا المسببة للعدوى مقاومة للمضاد الحيوي المعطى. وهذا يعني أنها تستطيع البقاء على قيد الحياة، بل وحتى التضاعف بالرغم من تلقي المضاد الحيوي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تصبح البكتيريا مقاومة للمضادات الحيوية لأسباب عديدة. ويمكن أن يساعد استخدام المضادات الحيوية بعناية في تقليل فرصة أن تصبح البكتيريا مقاومة لها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عندما يصف لك طبيبك دورة علاجية من أحد المضادات الحيوية، فإن الغرض منها هو علاج مرضك الحالي فقط. سيساعد الانتباه إلى النصائح التالية على منع ظهور البكتيريا المقاومة التي يمكن أن توقف عمل المضاد الحيوي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">۱. من المهم للغاية أن تتناول المضاد الحيوي بالجرعة الصحيحة وفي الأوقات الصحيحة ولمدة العدد الصحيح من الأيام. اقرأ التعليمات الموجودة على الملصق وإذا تعذر عليك فهم أي شيء، فاطلب من طبيبك أو الصيدلي شرحه لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">۲. ينبغي ألا تتناول مضادًا حيويًا إلا إذا تم وصفه لك خصيصًا وينبغي أن تستخدمه فقط لعلاج العدوى التي وُصف لعلاجها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">۳. ينبغي ألا تتناول مضادات حيوية موصوفة لأشخاص آخرين، حتى إذا كانت العدوى التي أصيبوا بها مشابهة لتلك التي تعاني منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">٤. ينبغي ألا تُعطي المضادات الحيوية الموصوفة لك إلى أشخاص آخرين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">٥. إذا تبقى لديك أي كمية من مضاد حيوي بعد تلقيك الدورة العلاجية وفقًا لتوجيهات طبيبك، ينبغي أن تأخذ الكمية المتبقية إلى صيدلية من أجل التخلص منها بالشكل المناسب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت مصابًا &nbsp;بحالة تتطلب منك مراقبة نسبة الصوديوم التي تتناولها، يرجى إبلاغ طبيبك أو الصيدلي أو الممرض (ة).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">خذ هذا الدواء دائمًا وفقًا لوصفة الطبيب أو الصيدلي أو الممرض(ة) تمامًا. يجب عليك التحقق من الطبيب أو من الصيدلي أو الممرض(ة) إذا لم تكن متأكدًا.</p><p dir="RTL">&nbsp;</p><p>تناول المستحضر من قبل البالغين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعتمد الجرعة على نوع العدوى التي تعاني منها، ومكان العدوى في الجسم، ومدى خطورة العدوى. سيقرر الطبيب الجرعة التي تحتاج إليها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عادةً ما تتراوح الجرعة الخاصة بالبالغين بين ٥۰۰&nbsp;ملجم (مليجرام) و۲&nbsp;جم (جرام). وعادةً ما ستتلقى جرعة كل ٨ ساعات. ولكن قد تتلقى جرعة بمعدل أقل تكرارًا إذا كانت كليتاك لا تعملان كما ينبغي.</p><p dir="RTL">&nbsp;</p><p>تناول المستحضر من قبل الأطفال والمراهقين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُحدد الجرعة الخاصة بالأطفال الأكبر من ۳ أشهر وحتى ۱۲ عامًا باستخدام عمر ووزن الطفل. تتراوح الجرعة الموصى بها بين ۱۰ ملجم و٤۰ ملجم من ميرونيم لكل كيلوجرام (كلجم) من وزن الطفل. عادةً ما تُعطى جرعة كل ٨ ساعات. الأطفال الذين</p><p dir="RTL">يزيد وزنهم عن ٥۰ كلجم سيتم إعطاؤهم جرعة خاصة بالبالغين.</p><p dir="RTL">&nbsp;</p><p>طريقة استخدام ميرونيم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيتم إعطاؤك ميرونيم في صورة حقن أو تسريب في وريد كبير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عادةً ما سيقوم الطبيب أو الممرض(ة) بإعطائك ميرونيم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالرغم من ذلك، يتم تدريب بعض المرضى وأولياء الأمور ومقدمي الرعاية لإعطاء ميرونيم في المنزل.</p><p dir="RTL">تتوفر تعليمات القيام بهذا الأمر في هذه النشرة (في القسم &nbsp;المُسمى &nbsp;&quot;تعليمات إعطاء ميرونيم لنفسك أو لشخص آخر في المنزل&quot;). خذ هذا الدواء دائمًا وفقًا لوصفة الطبيب تمامًا. يجب عليك التحقق من الطبيب إذا لم تكن متأكدًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي عدم خلط حقنتك بمحاليل تحتوي على أدوية أخرى أو إضافتها إليها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تستغرق عملية الحقن ٥ دقائق تقريبًا أو من ۱٥ إلى ۳۰ دقيقة. سيخبرك الطبيب بكيفية إعطاء ميرونيم.</p><p dir="RTL">ينبغي عادةً أن تتلقى الحقن الخاصة بك في نفس الأوقات كل يوم.</p><p dir="RTL">&nbsp;</p><p>أ&zwnj;-&nbsp;&nbsp;&nbsp; الجرعة الزائدة من ميرونيم</p><p dir="RTL">إذا استخدمت عن طريق الخطأ جرعة أكبر من الجرعة الموصوفة لك، فاتصل بالطبيب أو أقرب مستشفى فورًا.</p><p dir="RTL">&nbsp;</p><p>ب&zwnj;- نسيان تناول جرعة ميرونيم</p><p dir="RTL">إذا &nbsp;فوتّ &nbsp;إحدى الحقن، ينبغي أن تأخذها في أقرب وقت ممكن. بالرغم من ذلك، إذا كان موعد تلقي حقنتك التالية &nbsp;وشيكًا ، فتخط الحقنة الفائتة. لا تأخذ جرعة مضاعفة (حقنتين في نفس الوقت) للتعويض عن الجرعة التي أغفلتها.</p><p dir="RTL">&nbsp;</p><p>ج- التوقف عن تناول ميرونيم</p><p dir="RTL">لا تتوقف عن استخدام ميرونيم حتى يخبرك الطبيب بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حال وجود أي استفسارات أخرى تتعلق بالمستحضر قم بالتواصل مع الطبيب أو الصيدلي أو الممرض(ة).</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية. إلا أنها قد لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p>تفاعلات الحساسية الشديدة</p><p dir="RTL">إذا أصبت بأي من هذه العلامات والأعراض،<strong> فأخبر طبيبك أو الممرضة فورًا</strong>. فقد تحتاج إلى علاج طبي عاجل. قد تتضمن العلامات والأعراض بدء الحالات التالية فجأة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي الشديد، أو الحكة، أو الشرى على الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه، أو الشفتين، أو اللسان، أو أجزاء أخرى من الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس، أو الأزيز، أو صعوبة التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التفاعلات الجلدية الخطيرة التي تتضمن</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات فرط الحساسية الخطيرة التي تشمل الحمى، والطفح الجلدي، والتغيرات في نتائج فحوصات الدم التي تُظهر مدى كفاءة عمل الكبد (زيادة مستويات إنزيمات الكبد)، وزيادة أحد أنواع خلايا الدم البيضاء (فرط اليوزينات)، وتضخم العقد الليمفاوية. قد تكون هذه علامات الإصابة باضطراب حساسية يصيب أعضاءً متعددة يُعرف بمتلازمة التفاعل الدوائي المصحوب بكثرة اليوزينيات وأعراض جهازية (DRESS).</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي القشري الأحمر شديد الحدة، ظهور نتوءات جلدية بها صديد، ظهور بثور أو تقشر الجلد، وهو ما قد يصحبه حمى شديدة وألم في المفاصل.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات الطفح الجلدي الشديد التي يمكن أن تظهر في شكل بقع دائرية مائلة إلى الأحمر غالبًا ما توجد بثور في منتصفها وتنتشر على الجذع، أو تقشر الجلد، أو قرح في الفم والحلق والأنف والأعضاء التناسلية والعينين، ويمكن أن تكون مسبوقة بحمى و/أو أعراض شبيهة بالإنفلونزا (متلازمة ستيفنز-جونسون) أو شكل أشد حدة (تقشر الأنسجة المتموتة البشروية التسممي).</p><p dir="RTL">&nbsp;</p><p>تلف خلايا الدم الحمراء (معدل التكرار غير معروف)</p><p dir="RTL">تتضمن العلامات:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم القدرة على التنفس في أوقات غير متوقعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير لون البول إلى الأحمر أو البني.</p><p dir="RTL">إذا لاحظت أيًا &nbsp;مما &nbsp;ورد أعلاه، <strong>فاذهب إلى طبيب فورًا</strong>. <strong>الأعراض الجانبية المحتملة الأخرى:</strong></p><p>شائعة (قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰ أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم البطن (المعدة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور برغبة في التقيؤ (الغثيان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيؤ (القيء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي، حكة الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم والالتهاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة عدد الصفائح الدموية في دمك (تظهر في نتائج فحص الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود تغيرات في نتائج فحوصات الدم، بما في ذلك الاختبارات التي تظهر مدى كفاءة عمل كبدك.</p><p dir="RTL">&nbsp;</p><p>غير شائعة (قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰۰ شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود تغيرات في دمك. تتضمن هذه التغيرات انخفاض عدد الصفائح الدموية (مما قد يجعلك تتكدّم بسهولة أكبر)، وزيادة عدد بعض خلايا الدم البيضاء، وانخفاض عدد خلايا دم بيضاء أخرى، وزيادة كمية مادة تُسمى &quot;البيليروبين&quot;. قد يجري الطبيب فحوصات دم من حين إلى آخر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود تغيرات في نتائج فحوصات الدم، بما في ذلك الاختبارات التي تظهر مدى كفاءة عمل كليتك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بوخز (الشكشكة والوخز).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات عدوى الفم أو المهبل الناتجة عن الفطريات (القلاع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأمعاء المصحوب بإسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرح الأوردة التي حُقن فيها ميرونيم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود تغيرات أخرى في دمك. تتضمن الأعراض حالات العدوى المتكررة، وارتفاع درجة الحرارة، واحتقان الحلق. قد يجري الطبيب فحوصات دم من حين إلى آخر.</p><p dir="RTL">&nbsp;</p><p>نادرة (قد تصيب ما يصل إلى شخص واحد من بين كل ۱۰۰۰ شخص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات (التشنجات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التوهان والارتباك الحاد (الهذيان).</p><p dir="RTL">&nbsp;</p><p>لوحظت حالات إصابة بألم الصدر المفاجئ، الذي قد يدل على احتمالية حدوث تفاعل حساسية خطير يُسمى متلازمة كونس، مع أدوية أخرى من النوع نفسه. إذا تعرضت لهذا الأمر، فتحدث إلى أحد الأطباء أو الممرضة على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL"><br />إذا أصبت بأي آثار جانبية، فتحدث إلى طبيبك أو الصيدلي أو الممرضة. يتضمن هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرةً وفقًا لمتطلباتها المحلية بالدولة. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ل</strong><strong>لإبلاغ عن الأعراض الجانبية:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية:</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><ul><li dir="RTL">مركز الاتصال: ۱۹۹۹۹</li><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa/</li></ul></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دول الخليج الأخرى:</p><p dir="RTL">&nbsp;</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة </em></p></td></tr></tbody></table></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">قم بتخزين المستحضر بعيدًا عن متناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل ميرونيم الذي يؤخذ عبر الوريد بعد انتهاء تاريخ الصلاحية والمذكور على العبوة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم في الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يخزّن في درجة حرارة اكثرمن ۳۰ درجة مئوية.</p><p dir="RTL">&nbsp;</p><p>الحقن</p><p dir="RTL">بعد التحضير: ينبغي استخدام المحاليل المحضَرة للحقن عن طريق الوريد فورًا. الفاصل الزمني بين بداية التحضير ونهاية عملية الحقن عن طريق الوريد ينبغي ألا يتعدى:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ۳ ساعات عند التخزين في درجة حرارة تصل إلى ۲٥ درجة مئوية؛</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ۱۲ ساعة عند التخزين في ظروف تبريد (من درجتين مئويتين إلى ٨ درجات مئوية).</p><p dir="RTL">&nbsp;</p><p>التسريب</p><p dir="RTL">&nbsp;</p><p dir="RTL">بعد التحضير: ينبغي استخدام المحاليل المحضَرة للتسريب عن طريق الوريد فورًا. الفاصل الزمني بين بداية التحضير ونهاية عملية التسريب عن طريق الوريد ينبغي ألا يتعدى:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ۳ ساعات عند التخزين في درجة حرارة تصل إلى ۲٥ درجة مئوية عند إذابة ميرونيم في كلوريد الصوديوم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ۲٤ ساعة عند التخزين في ظروف تبريد (من درجتين مئويتين إلى ٨ درجات مئوية) عند إذابة ميرونيم في كلوريد الصوديوم؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند إذابة ميرونيم في دكستروز، ينبغي استخدام المحلول فورًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من وجهة نظر ميكروبيولوجية، ينبغي استخدام المنتج فورًا إلا إذا كانت طريقة الفتح/التحضير/التخفيف تستبعد خطر التلوث الميكروبيولوجي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم يُستخدم المنتج &nbsp;فورًا ، فإن مسؤولية مدة وظروف التخزين أثناء الاستخدام تقع على عاتق المستخدم. لا تقم بتجميد المحلول المحضَر.</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد في حاجة إليها. ستساعد هذه الإجراءات على حماية البيئة</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المادة الفعالة هي ميروبينيم ثلاثي الهيدرات بمقدار يعادل ٥۰۰ ملجم من ميروبينيم لا مائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المادة الفعالة هي ميروبينيم ثلاثي الهيدرات بمقدار يعادل ۱ جم من ميروبينيم لا مائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المكون الآخر هو كربونات الصوديوم اللا مائية.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميرونيم هو مسحوق معبأ في قارورة لونه أبيض إلى أصفر فاتح ومخصص لتحضير محلول للحقن أو التسريب.</p><p dir="RTL">العبوات بها ۱۰ قوارير.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <table cellspacing="0" cellpadding="0" align="center"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>مالك حق التسويق:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">Pfizer Limited,</p><p dir="RTL">&nbsp;Ramsgate Road, Kent, CT 13, 9 NJ, Sandwich, United Kingdom</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة:</strong></p><p dir="RTL">ACS Dobfar SpA, Tribiano, Milan, Italy</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو/أيار ۲۰۲٤
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Meronem IV 500 mg powder for solution for injection or infusion
Meronem IV 1 g powder for solution for injection or infusion

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Meronem IV 500 mg
Each vial contains meropenem trihydrate equivalent to 500 mg anhydrous meropenem.

Meronem IV 1 g
Each vial contains meropenem trihydrate equivalent to 1 g anhydrous meropenem.

Excipients with known effect:

Each 500 mg vial contains 104 mg sodium carbonate which equates to approximately 2 mEq of sodium (approximately 45 mg).
Each 1 g vial contains 208 mg sodium carbonate which equates to approximately 4 mEq of sodium (approximately 90 mg).
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for solution for injection or infusion.
A white to light yellow powder.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Meronem is indicated for the treatment of the following infections in adults and children aged 3 months and older (see sections 4.4 and 5.1):</p><p>&bull; Severe pneumonia, including hospital and ventilator-associated pneumonia.</p><p>&bull; Broncho-pulmonary infections in cystic fibrosis</p><p>&bull; Complicated urinary tract infections</p><p>&bull; Complicated intra-abdominal infections</p><p>&bull; Intra- and post-partum infections</p><p>&bull; Complicated skin and soft tissue infections</p><p>&bull; Acute bacterial meningitis</p><p>&nbsp;</p><p>Meronem may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.</p><p>&nbsp;</p><p>Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.</p><p>&nbsp;</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The tables below provide general recommendations for dosing.</p><p>&nbsp;</p><p>The dose of meropenem administered and the duration of treatment should take into account the type of infection to be treated, including its severity, and the clinical response.</p><p>&nbsp;</p><p>A dose of up to 2 g three times daily in adults and adolescents and a dose of up to 40 mg/kg three times daily in children may be particularly appropriate when treating some types of infections, such as infections due to less susceptible bacterial species (e.g. <em>Enterobacteriaceae</em>, <em>Pseudomonas aeruginosa,</em> <em>Acinetobacter </em>spp.), or very severe infections.</p><p>&nbsp;</p><p>Additional considerations for dosing are needed when treating patients with renal insufficiency (see further below).</p><p>&nbsp;</p><p><strong>Adults and adolescents</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Infection </strong></p></td><td style="vertical-align:top"><p><strong>Dose to be administered every 8 hours </strong></p></td></tr><tr><td style="vertical-align:top"><p>Severe pneumonia including hospital and ventilator-associated pneumonia.</p></td><td style="vertical-align:top"><p>500 mg or 1 g</p></td></tr><tr><td style="vertical-align:top"><p>Broncho-pulmonary infections in cystic fibrosis</p></td><td style="vertical-align:top"><p>2 g</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections</p></td><td style="vertical-align:top"><p>500 mg or 1 g</p></td></tr><tr><td style="vertical-align:top"><p>Complicated intra-abdominal infections</p></td><td style="vertical-align:top"><p>500 mg or 1 g</p></td></tr><tr><td style="vertical-align:top"><p>Intra- and post-partum infections</p></td><td style="vertical-align:top"><p>500 mg or 1 g</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td><td style="vertical-align:top"><p>500 mg or 1 g</p></td></tr><tr><td style="vertical-align:top"><p>Acute bacterial meningitis</p></td><td style="vertical-align:top"><p>2 g</p></td></tr><tr><td style="vertical-align:top"><p>Management of febrile neutropenic patients</p></td><td style="vertical-align:top"><p>1 g</p></td></tr></tbody></table><p>Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes (see sections 6.2, 6.3 and 6.6).</p><p>Alternatively, doses up to 1 g can be given as an intravenous bolus injection over approximately 5 minutes. There are limited safety data available to support the administration of a 2 g dose in adults as an intravenous bolus injection.</p><p><u>Renal impairment</u></p><p>The dose for adults and adolescents should be adjusted when creatinine clearance is less than 51 ml/min, as shown below. There are limited data to support the administration of these dose adjustments for a unit dose of 2 g.</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Creatinine clearance (ml/min)</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p><p>(based on &ldquo;unit&rdquo; dose range of 500 mg or 1 g or 2 g, see table above)</p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>26-50</p></td><td style="vertical-align:top"><p>one unit dose</p></td><td style="vertical-align:top"><p>every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p>10-25</p></td><td style="vertical-align:top"><p>half of one unit dose</p></td><td style="vertical-align:top"><p>every 12 hours</p></td></tr><tr><td style="vertical-align:top"><p>&lt;10</p></td><td style="vertical-align:top"><p>half of one unit dose</p></td><td style="vertical-align:top"><p>every 24 hours</p></td></tr></tbody></table><p>Meropenem is cleared by haemodialysis and haemofiltration. The required dose should be administered after completion of the haemodialysis cycle.</p><p>&nbsp;</p><p>There are no established dose recommendations for patients receiving peritoneal dialysis.</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p>No dose adjustment is necessary in patients with hepatic impairment (see section 4.4).</p><p>&nbsp;</p><p><u>Dose in elderly patients</u></p><p>No dose adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 ml/min.</p><p>&nbsp;</p><p><strong>Paediatric population</strong></p><p><u>Children under 3 months of age</u></p><p>The safety and efficacy of meropenem in children under 3 months of age have not been established and the optimal dose regimen has not been identified. However, limited pharmacokinetic data suggest that 20 mg/kg every 8 hours may be an appropriate regimen (see section 5.2).</p><p><u>Children from 3 months to 11 years of age and up to 50 kg body weight</u></p><p>The recommended dose regimens are shown in the table below:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Infection</strong></p></td><td style="vertical-align:top"><p><strong>Dose to be administered every 8 hours</strong></p></td></tr><tr><td style="vertical-align:top"><p>Severe pneumonia including hospital and ventilator-associated pneumonia</p></td><td style="vertical-align:top"><p>10 or 20 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Broncho-pulmonary infections in cystic fibrosis</p></td><td style="vertical-align:top"><p>40 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections</p></td><td style="vertical-align:top"><p>10 or 20 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Complicated intra-abdominal infections</p></td><td style="vertical-align:top"><p>10 or 20 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td><td style="vertical-align:top"><p>10 or 20 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Acute bacterial meningitis</p></td><td style="vertical-align:top"><p>40 mg/kg</p></td></tr><tr><td style="vertical-align:top"><p>Management of febrile neutropenic patients</p></td><td style="vertical-align:top"><p>20 mg/kg</p></td></tr></tbody></table><p><u>Children over 50 kg body weight</u></p><p>The adult dose should be administered.</p><p>There is no experience in children with renal impairment.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Meropenem is usually given by intravenous infusion over approximately 15 to 30 minutes (see sections 6.2, 6.3, and 6.6). Alternatively, meropenem doses of up to 20 mg/kg may be given as an intravenous bolus over approximately 5 minutes. There are limited safety data available to support the administration of a 40 mg/kg dose in children as an intravenous bolus injection.</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Hypersensitivity to any other carbapenem antibacterial agent.
Severe hypersensitivity (e.g. anaphylactic reaction, severe skin reaction) to any other type of beta-lactam antibacterial agent (e.g. penicillins or cephalosporins).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>The selection of meropenem to treat an individual patient should take into account the appropriateness of using a carbapenem antibacterial agent based on factors such as severity of the infection, the prevalence of resistance to other suitable antibacterial agents and the risk of selecting for carbapenem-resistant bacteria.</p><p>&nbsp;</p><p><em><u>Enterobacteriaceae</u></em><u>, </u><em><u>Pseudomonas aeruginosa</u></em><u> and <em>Acinetobacter </em>spp. resistance</u></p><p>Resistance to penems of <em>Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter</em> spp. varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in these bacteria to penems.</p><p>&nbsp;</p><p><u>Hypersensitivity reactions</u></p><p>As with all beta-lactam antibiotics, serious and occasionally fatal hypersensitivity reactions have been reported (see sections 4.3 and 4.8).</p><p>Patients who have a history of hypersensitivity to carbapenems, penicillins or other beta-lactam antibiotics may also be hypersensitive to meropenem. Before initiating therapy with meropenem, careful inquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics.</p><p>&nbsp;</p><p>If a severe allergic reaction occurs, the medicinal product should be discontinued and appropriate measures taken. Severe cutaneous adverse reactions (SCAR), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), erythema multiforme (EM) and acute generalised exanthematous pustulosis (AGEP) have been reported in patients receiving meropenem (see section 4.8). If signs and symptoms suggestive of these reactions appear, meropenem should be withdrawn immediately and an alternative treatment should be considered.</p><p>&nbsp;</p><p>With other beta-lactam antibiotics there have been reports of hypersensitivity reactions which progressed to Kounis syndrome (acute allergic coronary arteriospasm that can result in myocardial infarction, see section 4.8).</p><p>&nbsp;</p><p><u>Rhabdomyolysis</u></p><p>Rhabdomyolysis has been reported with the use of meropenem. If signs or symptoms of rhabdomyolysis such as muscle pain, tenderness or weakness, dark urine, or elevated creatine phosphokinase are observed, meropenem should be discontinued and appropriate therapy initiated (see section 4.8).</p><p>&nbsp;</p><p><u>Antibiotic<em>-</em>associated colitis</u></p><p>Antibiotic-associated colitis and pseudomembranous colitis have been reported with nearly all anti-bacterial agents, including meropenem, and may range in severity from mild to life threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of meropenem (see section 4.8).</p><p>&nbsp;</p><p>Discontinuation of therapy with meropenem and the administration of specific treatment for <em>Clostridium difficile</em> should be considered. Medicinal products that inhibit peristalsis should not be given.</p><p>&nbsp;</p><p><u>Seizures</u></p><p>Seizures have infrequently been reported during treatment with carbapenems, including meropenem (see section 4.8).</p><p>&nbsp;</p><p><u>Hepatic function monitoring</u></p><p>Hepatic function should be closely monitored during treatment with meropenem due to the risk of hepatic toxicity (hepatic dysfunction with cholestasis and cytolysis) (see section 4.8).</p><p>Use in patients with liver disease: patients with pre-existing liver disorders should have liver function monitored during treatment with meropenem. There is no dose adjustment necessary (see section 4.2).</p><p>&nbsp;</p><p><u>Direct antiglobulin test (Coombs test) seroconversion</u></p><p>A positive direct or indirect Coombs test may develop during treatment with meropenem.</p><p><u>&nbsp;</u></p><p><u>Concomitant use with valproic acid/sodium valproate/valpromide</u></p><p>The concomitant use of meropenem and valproic acid/sodium valproate/valpromide is not recommended (see section 4.5).</p><p>Meronem contains sodium.</p><p>&nbsp;</p><p>Meronem 500 mg: This medicinal product contains 45 mg sodium per 500 mg vial, equivalent to 2.25% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p><p>&nbsp;</p><p>Meronem 1 g: This medicinal product contains 90 mg sodium per 1 g vial, equivalent to 4.5% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>4.8 </strong><strong>Undesirable </strong><strong>effects</strong></p><p>&nbsp;</p><p><u>Summary of the safety profile</u></p><p>In a review of 4,872 patients with 5,026 meropenem treatment exposures, meropenem-related adverse reactions most frequently reported were diarrhoea (2.3%), rash (1.4%), nausea/vomiting (1.4%) and injection site inflammation (1.1%). The most commonly reported meropenem-related laboratory adverse events were thrombocytosis (1.6%) and increased hepatic enzymes (1.5-4.3%).</p><p>&nbsp;</p><p><u>Tabulated risk of adverse reactions</u></p><p>In the table below all adverse reactions are listed by system organ class and frequency: very common (&ge; 1/10); common (&ge; 1/100 to &lt;1/10); uncommon (&ge; 1/1,000 to &lt;1/100); rare (&ge; 1/10,000 to &lt;1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="3" style="vertical-align:top"><p>Table 1</p></td></tr><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Frequency</p></td><td style="vertical-align:top"><p>Event</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>oral and vaginal candidiasis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>thrombocythaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>agranulocytosis, haemolytic anaemia</p><p>&nbsp;</p><p>shortened prothrombin time and shortened partial thromboplastin time, leukocytosis,</p><p>hypokalaemia</p><p>&nbsp;</p><p>thrombocytopenia, neutropenia, leukopenia, eosinophilia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>anaphylaxis (see sections 4.3 and 4.4)</p><p>angioedema</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;Psychiatric disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;Rare</p></td><td style="vertical-align:top"><p>&nbsp;delirium</p><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>convulsions (see section 4.4)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>diarrhoea, abdominal pain, vomiting, nausea</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>antibiotic-associated colitis (see section 4.4)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>transaminases increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>blood bilirubin increased</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>rash, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>toxic epidermal necrolysis, Stevens Johnson syndrome, erythema multiforme (see section 4.4), urticaria</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>drug reaction with eosinophilia and systemic symptoms , acute generalised exanthematous pustulosis (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>rhabdomyolysis</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>blood creatinine increased, blood urea increased</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>inflammation, pain</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>thrombophlebitis, pain at the injection site</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Description of selected adverse reactions</u></p><p><em>Kounis Syndrome</em></p><p>Acute coronary syndrome associated with an allergic reaction (Kounis syndrome) has been reported with other beta-lactam antibiotics (see section 4.4).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Meronem is licensed for children over 3 months of age. There is no evidence of an increased risk of any adverse drug reaction in children based on the limited available data. All reports received were consistent with events observed in the adult population.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local requirements.</p><p><strong>&nbsp;</strong></p><p><strong>To Report side effects</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center (NPC)</strong></p><p>Call center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific medicinal product interaction studies other than probenecid were conducted.</p><p>Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of meropenem with the effect of increasing the elimination half-life and plasma concentration of meropenem. Caution is required if probenecid is co-administered with meropenem.</p><p>&nbsp;</p><p>The potential effect of meropenem on the protein binding of other medicinal products or metabolism has not been studied. However, the protein binding is so low that no interactions with other compounds would be expected on the basis of this mechanism.</p><p>&nbsp;</p><p>Decreases in blood levels of valproic acid have been reported when it is co-administered with carbapenem agents resulting in a 60-100 % decrease in valproic acid levels in about two days.</p><p>&nbsp;</p><p>Due to the rapid onset and the extent of the decrease, co-administration of valproic acid/sodium valproate/valpromide with carbapenem agents is not considered to be manageable and therefore should be avoided (see section 4.4).</p><p>&nbsp;</p><p><u>Oral anti-coagulants</u></p><p>Simultaneous administration of antibiotics with warfarin may augment its anti-coagulant effects. There have been many reports of increases in the anti-coagulant effects of orally administered anti-coagulant agents, including warfarin in patients who are concomitantly receiving antibacterial agents. The risk may vary with the underlying infection, age and general status of the patient so that the contribution of the antibiotic to the increase in INR (international normalised ratio) is difficult to assess. It is recommended that the INR should be monitored frequently during and shortly after co-administration of antibiotics with an oral anti-coagulant agent.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong></p><p>There are no or limited amount of data from the use of meropenem in pregnant women.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p>As a precautionary measure, it is preferable to avoid the use of meropenem during pregnancy.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p>Small amounts of meropenem have been reported to be excreted in human milk. Meropenem should not be used in breast-feeding women unless the potential benefit for the mother justifies the potential risk to the baby.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effect on the ability to drive and use machines have been performed. However, when driving or operating machines, it should be taken into account that headache, paraesthesia and convulsions have been reported for meropenem.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Summary of the safety profile</u></p><p>In a review of 4,872 patients with 5,026 meropenem treatment exposures, meropenem-related adverse reactions most frequently reported were diarrhoea (2.3%), rash (1.4%), nausea/vomiting (1.4%) and injection site inflammation (1.1%). The most commonly reported meropenem-related laboratory adverse events were thrombocytosis (1.6%) and increased hepatic enzymes (1.5-4.3%).</p><p>&nbsp;</p><p><u>Tabulated risk of adverse reactions</u></p><p>In the table below all adverse reactions are listed by system organ class and frequency: very common (&ge; 1/10); common (&ge; 1/100 to &lt;1/10); uncommon (&ge; 1/1,000 to &lt;1/100); rare (&ge; 1/10,000 to &lt;1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td colspan="3" style="vertical-align:top"><p>Table 1</p></td></tr><tr><td style="vertical-align:top"><p>System Organ Class</p></td><td style="vertical-align:top"><p>Frequency</p></td><td style="vertical-align:top"><p>Event</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>oral and vaginal candidiasis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>thrombocythaemia</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>&nbsp;agranulocytosis, haemolytic anaemia</p><p>&nbsp;</p><p>shortened prothrombin time and shortened partial thromboplastin time, leukocytosis,</p><p>hypokalaemia</p><p>&nbsp;</p><p>thrombocytopenia, neutropenia, leukopenia, eosinophilia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>anaphylaxis (see sections 4.3 and 4.4)</p><p>angioedema</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>delirium</p><p>&nbsp;</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>convulsions (see section 4.4)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>diarrhoea, abdominal pain, vomiting, nausea</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>antibiotic-associated colitis (see section 4.4)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>transaminases increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>blood bilirubin increased</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>rash, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>toxic epidermal necrolysis, Stevens Johnson syndrome, erythema multiforme (see section4.4), urticaria</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>drug reaction with eosinophilia and systemic symptoms , acute generalised exanthematous pustulosis (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>blood creatinine increased, blood urea increased</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>inflammation, pain</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>thrombophlebitis, pain at the injection site</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Description of selected adverse reactions</u></p><p><em>Kounis Syndrome</em></p><p>Acute coronary syndrome associated with an allergic reaction (Kounis syndrome) has been reported with other beta-lactam antibiotics (see section 4.4).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Meronem is licensed for children over 3 months of age. There is no evidence of an increased risk of any adverse drug reaction in children based on the limited available data. All reports received were consistent with events observed in the adult population.</p><p>&nbsp;</p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions according to their local requirements.</p><p><strong>To Report side effects</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance Center ( NPC )</strong></p><p>Call center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa/&nbsp;&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Relative overdose may be possible in patients with renal impairment if the dose is not adjusted as described in section 4.2. Limited post-marketing experience indicates that if adverse reactions occur following overdose, they are consistent with the adverse reaction profile described in section 4.8, are generally mild in severity and resolve on withdrawal or dose reduction. Symptomatic treatments should be considered.</p><p>In individuals with normal renal function, rapid renal elimination will occur.</p><p>Haemodialysis will remove meropenem and its metabolite.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antibacterials for systemic use, carbapenems</p><p>ATC code: J01DH02</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Meropenem exerts its bactericidal activity by inhibiting bacterial cell wall synthesis in Gram-positive and Gram-negative bacteria through binding to penicillin-binding proteins (PBPs).</p><p>&nbsp;</p><p><u>Pharmacokinetic/Pharmacodynamic (PK/PD) relationship</u></p><p>Similar to other beta-lactam antibacterial agents, the time that meropenem concentrations exceed the MIC (T&gt;MIC) has been shown to best correlate with efficacy. In preclinical models meropenem demonstrated activity when plasma concentrations exceeded the MIC of the infecting organisms for approximately 40% of the dosing interval. This target has not been established clinically.</p><p>&nbsp;</p><p><u>Mechanism of resistance</u></p><p>Bacterial resistance to meropenem may result from: (1) decreased permeability of the outer membrane of Gram-negative bacteria (due to diminished production of porins) (2) reduced affinity of the target PBPs (3) increased expression of efflux pump components, and (4) production of beta-lactamases that can hydrolyse carbapenems.</p><p>Localised clusters of infections due to carbapenem-resistant bacteria have been reported in the European Union.</p><p>There is no target-based cross-resistance between meropenem and agents of the quinolone, aminoglycoside, macrolide and tetracycline classes. However, bacteria may exhibit resistance to more than one class of antibacterial agents when the mechanism involved include impermeability and/or an efflux pump(s).</p><p>&nbsp;</p><p><u>Breakpoints</u></p><p>MIC (minimum inhibitory concentration) interpretive criteria for susceptibility testing have been established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for meropenem and are listed here:</p><p>https://www.ema.europa.eu/documents/other/minimum-inhibitory-concentration-mic-breakpoints_en.xlsx<br />&nbsp;</p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p>&nbsp;</p><p>The following table of pathogens listed is derived from clinical experience and therapeutic guidelines.</p><p>&nbsp;</p><p><u>Commonly susceptible species</u></p><p><u>Gram-positive aerobes</u></p><p><em>Enterococcus faecalis </em><sup>$</sup></p><p><em>Staphylococcus aureus </em>(methicillin-susceptible<em>) </em><sup>&pound;</sup></p><p><em>Staphylococcus </em>species (methicillin-susceptible) including <em>Staphylococcus epidermidis</em></p><p><em>Streptococcus agalactiae</em> (Group B)</p><p><em>Streptococcus milleri</em> group (<em>S. anginosus</em>, <em>S. constellatus</em>, and <em>S. intermedius</em>)</p><p><em>Streptococcus pneumoniae</em></p><p><em>Streptococcus pyogenes</em> (Group A)</p><p><u>Gram-negative aerobes</u></p><p><em>Citrobacter freundii</em></p><p><em>Citrobacter koseri</em></p><p><em>Enterobacter aerogenes</em></p><p><em>Enterobacter cloacae</em></p><p><em>Escherichia coli</em></p><p><em>Haemophilus influenzae</em></p><p><em>Klebsiella oxytoca</em></p><p><em>Klebsiella pneumoniae</em></p><p><em>Morganella morganii</em></p><p><em>Neisseria meningitidis</em></p><p><em>Proteus mirabilis</em></p><p><em>Proteus vulgaris</em></p><p><em>Serratia marcescens</em></p><p><u>Gram-positive anaerobes</u></p><p><em>Clostridium perfringens</em></p><p><em>Peptoniphilus asaccharolyticus</em></p><p><em>Peptostreptococcus</em> species (including <em>P. micros, P anaerobius, P. magnus</em>)</p><p><u>Gram-negative anaerobes</u></p><p><em>Bacteroides caccae</em></p><p><em>Bacteroides fragilis</em> group</p><p><em>Prevotella bivia</em></p><p><em>Prevotella disiens</em></p><p>&nbsp;</p><p><strong>Species for which acquired resistance may be a problem</strong></p><p><u>Gram-positive aerobes</u></p><p><em>Enterococcus faecium </em><sup>$</sup><sup>&dagger;</sup></p><p><u>Gram-negative aerobes</u></p><p><em>Acinetobacter </em>species</p><p><em>Burkholderia cepacia</em></p><p><em>Pseudomonas aeruginosa</em></p><p>&nbsp;</p><p><strong>Inherently resistant organisms</strong></p><p><u>Gram-negative aerobes</u></p><p><em>Stenotrophomonas maltophilia</em></p><p><em>Legionella </em>species</p><p>&nbsp;</p><p><strong>Other micro-organisms</strong></p><p><em>Chlamydophila pneumoniae</em></p><p><em>Chlamydophila psittaci</em></p><p><em>Coxiella burnetii</em></p><p><em>Mycoplasma pneumoniae</em></p><p><sup>$</sup> Species that show natural intermediate susceptibility</p><p><sup>&pound; </sup>All methicillin-resistant staphylococci are resistant to meropenem</p><p><sup>&dagger; </sup>Resistance rate &ge; 50% in one or more EU countries.</p><p>Glanders and melioidosis: Use of meropenem in humans is based on<em> in vitro B.mallei </em>and <em>B. pseudomallei </em>susceptibility data and on limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of glanders and melioidosis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In healthy subjects the mean plasma half-life is approximately 1 hour; the mean volume of distribution is approximately 0.25 l/kg (11-27 l) and the mean clearance is 287 ml/min at 250 mg falling to 205 ml/min at 2 g. Doses of 500, 1000 and 2000 mg doses infused over 30 minutes give mean Cmax values of approximately 23, 49 and 115 &mu;g/ml respectively, corresponding AUC values were 39.3, 62.3 and 153 &mu;g.h/ml. After infusion over 5 minutes Cmax values are 52 and 112 &mu;g/ml after 500 and 1000 mg doses respectively. When multiple doses are administered 8-hourly to subjects with normal renal function, accumulation of meropenem does not occur.</p><p>A study of 12 patients administered meropenem 1000 mg 8 hourly post-surgically for intra-abdominal infections showed a comparable Cmax and half-life to normal subjects but a greater volume of distribution 27 l.</p><p>&nbsp;</p><p><strong>Distribution</strong></p><p>The average plasma protein binding of meropenem was approximately 2% and was independent of concentration. After rapid administration (5 minutes or less) the pharmacokinetics are biexponential but this is much less evident after 30 minutes infusion. Meropenem has been shown to penetrate well into several body fluids and tissues: including lung, bronchial secretions, bile, cerebrospinal fluid, gynaecological tissues, skin, fascia, muscle, and peritoneal exudates.</p><p>&nbsp;</p><p><strong>Biotransformation</strong></p><p>Meropenem is metabolised by hydrolysis of the beta-lactam ring generating a microbiologically inactive metabolite. In vitro meropenem shows reduced susceptibility to hydrolysis by human dehydropeptidase-I (DHP-I) compared to imipenem and there is no requirement to co-administer a DHP-I inhibitor.</p><p>&nbsp;</p><p><strong>Elimination</strong></p><p>Meropenem is primarily excreted unchanged by the kidneys; approximately 70% (50 &ndash;75%) of the dose is excreted unchanged within 12 hours. A further 28% is recovered as the microbiologically inactive metabolite. Faecal elimination represents only approximately 2% of the dose. The measured renal clearance and the effect of probenecid show that meropenem undergoes both filtration and tubular secretion.</p><p>&nbsp;</p><p><strong>Renal insufficiency</strong></p><p>Renal impairment results in higher plasma AUC and longer half-life for meropenem. There were AUC increases of 2.4 fold in patients with moderate impairment (CrCL 33-74 ml/min), 5 fold in severe impairment (CrCL 4-23 ml/min) and 10 fold in haemodialysis patients (CrCL &lt;2 ml/min) when compared to healthy subjects (CrCL &gt;80 ml/min). The AUC of the microbiologically inactive ring opened metabolite was also considerably increased in patients with renal impairment. Dose adjustment is recommended for patients with moderate and severe renal impairment (see section 4.2).</p><p>Meropenem is cleared by haemodialysis with clearance during haemodialysis being approximately 4 times higher than in anuric patients.</p><p>&nbsp;</p><p><strong>Hepatic insufficiency</strong></p><p>A study in patients with alcoholic cirrhosis shows no effect of liver disease on the pharmacokinetics of meropenem after repeated doses.</p><p>&nbsp;</p><p><strong>Adult patients</strong></p><p>Pharmacokinetic studies performed in patients have not shown significant pharmacokinetic differences versus healthy subjects with equivalent renal function. A population model developed from data in 79 patients with intra-abdominal infection or pneumonia, showed a dependence of the central volume on weight and the clearance on creatinine clearance and age.</p><p>&nbsp;</p><p><strong>Paediatric population</strong></p><p>The pharmacokinetics in infants and children with infection at doses of 10, 20 and 40 mg/kg showed Cmax values approximating to those in adults following 500, 1000 and 2000 mg doses, respectively. Comparison showed consistent pharmacokinetics between the doses and half-lives similar to those observed in adults in all but the youngest subjects (&lt;6 months t1/2 1.6 hours). The mean meropenem clearance values were 5.8 ml/min/kg (6-12 years), 6.2 ml/min/kg (2-5 years), 5.3 ml/min/kg (6-23 months) and 4.3 ml/min/kg (2-5 months). Approximately 60% of the dose is excreted in urine over 12 hours as meropenem with a further 12% as metabolite. Meropenem concentrations in the CSF of children with meningitis are approximately 20% of concurrent plasma levels although there is significant inter-individual variability.</p><p>The pharmacokinetics of meropenem in neonates requiring anti-infective treatment showed greater clearance in neonates with higher chronological or gestational age with an overall average half-life of 2.9 hours. Monte Carlo simulation based on a population PK model showed that a dose regimen of 20 mg/kg 8 hourly achieved 60%T&gt;MIC for <em>P. aeruginosa</em> in 95% of pre-term and 91% of full term neonates.</p><p>&nbsp;</p><p><strong>Elderly</strong></p><p>Pharmacokinetic studies in healthy elderly subjects (65-80 years) have shown a reduction in plasma clearance, which correlated with age-associated reduction in creatinine clearance, and a smaller reduction in non-renal clearance. No dose adjustment is required in elderly patients, except in cases of moderate to severe renal impairment (see section 4.2).</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal studies indicate that meropenem is well tolerated by the kidney. Histological evidence of renal tubular damage was seen in mice and dogs only at doses of 2000 mg/kg and above after a single administration and above and in monkeys at 500 mg/kg in a 7-day study.</p><p>Meropenem is generally well tolerated by the central nervous system. Effects were seen in acute toxicity studies in rodent at doses exceeding 1000 mg/kg.</p><p>The IV LD<sub>50</sub> of meropenem in rodents is greater than 2000 mg/kg.</p><p>In repeat dose studies of up to 6 months duration only minor effects were seen including a decrease in red cell parameters in dogs.</p><p>There was no evidence of mutagenic potential in a conventional test battery and no evidence of reproductive toxicity including teratogenic potential in studies in rats up to 750 mg/kg and in monkeys up to 360 mg/kg.</p><p>There was no evidence of increased sensitivity to meropenem in juveniles compared to adult animals. The intravenous formulation was well tolerated in animal studies.</p><p>The sole metabolite of meropenem had a similar profile of toxicity in animal studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium carbonate anhydrous</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use Meronem after the expiry date which is stated on the carton / Blister after EXP:. The expiry date refers to the last day of that month
48 months

After reconstitution:
Intravenous bolus injection administration
A solution for bolus injection is prepared by dissolving the drug product in water for injection to a final concentration of 50 mg/ml. Chemical and physical in-use stability for a prepared solution for bolus injection has been demonstrated for 3 hours at up to 25°C or 12 hours under refrigerated conditions (2-8°C).

From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately.

If not used immediately in-use storage times and conditions are the responsibility of the user.

Intravenous infusion administration 
A solution for infusion is prepared by dissolving the drug product in either 0.9% sodium chloride solution for infusion or 5% dextrose solution for infusion to a final concentration of 1 to 20 mg/ml. 
Chemical and physical in-use stability for a prepared solution for infusion using 0.9% sodium chloride solution has been demonstrated for 3 hours at up to 25°C or 24 hours under refrigerated conditions (2-8°C). 
From a microbiological point of view, unless the method of opening/reconstitution/dilution precludes the risk of microbiological contamination, the product should be used immediately. 
If not used immediately in-use storage times and conditions are the responsibility of the user.
Reconstituted solution of the product in 5% dextrose solution should be used immediately.
The constituted solutions should not be frozen.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Do not freeze the reconstituted solution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Meronem 500 mg</p><p>20 ml Type 1 glass vial with stopper (grey halobutilic rubber with an aluminium cap)</p><p>&nbsp;</p><p>Meronem 1 g</p><p>30 ml Type 1 glass vial with stopper (grey halobutilic rubber with an aluminium cap)</p><p>The medicinal product is supplied in pack sizes of 10 vials.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Injection</u></p><p>Meropenem to be used for bolus intravenous injection should be constituted with sterile water for injection.</p><p>&nbsp;</p><p><u>Infusion</u></p><p>For intravenous infusion meropenem vials may be directly constituted with 0.9% sodium chloride or 5% dextrose solutions for infusion.</p><p>&nbsp;</p><p>Each vial is for single use only.</p><p>&nbsp;</p><p>Standard aseptic techniques should be used for solution preparation and administration.</p><p>&nbsp;</p><p>The solution should be shaken before use.</p><p>&nbsp;</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing authorization holder

Pfizer Limited, Ramsgate Road, Kent , CT 13, 9 NJ, Sandwich, United kingdom

Manufacturer:
ACS Dobfar SpA, Tribiano, Milan, Italy

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>